Breaking News Instant updates and real-time market news.

INCY

Incyte

$133.42

0.2 (0.15%)

, GILD

Gilead

$70.58

0.78 (1.12%)

07:15
07/14/17
07/14
07:15
07/14/17
07:15

Acquisition of Incyte would make sense for Gilead, says Leerink

Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.

INCY

Incyte

$133.42

0.2 (0.15%)

GILD

Gilead

$70.58

0.78 (1.12%)

  • 26

    Jul

  • 01

    Aug

INCY Incyte
$133.42

0.2 (0.15%)

06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.
06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Incyte could see a 9% increment in value, says Oppenheimer
Oppenheimer analyst Jay Olson says Incyte's shares could see a 9% increment in value if the July 25 pipeline update on Olumiant is favorable pointing to a resubmission post-CRL without any new clinical trials required. Separately, Incyte's valuation could reduce by around 11% in the analyst's worst case scenario if read across from MYSTIC is negative based on a positive result for the PD-L1 plus CTLA-4 combo versus chemo in 1L NSCLC all comers.
GILD Gilead
$70.58

0.78 (1.12%)

07/03/17
COWN
07/03/17
NO CHANGE
Target $90
COWN
Outperform
Gilead raised prices on several drugs by 6.9%, says Cowen
Third party sources indicate that Gilead Sciences increased the U.S. prices of several products by 6.9%, Cowen analyst Phil Nadeau tells investors in a research note. The analyst notes the increases are consistent with Gilead's historical practice, which is to raise the prices of most of its medicines once per year. Nadeau adds that Genvoya's discount to Stribild was restored to 11%, which he believes should help maintain the momentum of Genvoya's launch. The analyst maintains an Outperform rating on Gilead.
07/05/17
SBSH
07/05/17
NO CHANGE
Target $65
SBSH
Neutral
Merck could become market leader in HIV, says Citi
In a research note titled "EFdA - The Remarkable HIV Drug That Could End GILD/ViiV's Dominance," Citi analyst Andrew Baum says he finds it likely that Merck (MRK) could become a market leader in HIV treatment. Given EFdA's profile, Merck intends to develop an oral daily single tablet coformulated with Isentress HD or another oral antiretroviral for HIV-infected patients, Baum tells investors in a research note. He models first EFdA approval as early as 2021 and believes commercial success could add $5B per year to sales forecasts. The analyst keeps a Neutral rating on Merck with a $65 price target.
07/10/17
JEFF
07/10/17
INITIATION
Target $80
JEFF
Gilead assumed with a Hold at Jefferies
Jefferies analyst Michael Yee assumed coverage on Gilead with a Hold and an $80 price target.
07/13/17
BARD
07/13/17
NO CHANGE
Target $87
BARD
Outperform
Baird likes Gilead heading into Q2 earnings
Baird analyst Brian Skorney said he likes Gilead heading into Q2 earnings. The analyst said Hep-C sales should beat estimates and predicts its sales decline should be approaching a plateau, which would result in upside to the shares. He said the operating results could provide much needed stability, which should also result in upside. Skorney maintained his Outperform rating and $87 price target on Gilead shares.

TODAY'S FREE FLY STORIES

MET

MetLife

$54.65

0.07 (0.13%)

18:20
07/21/17
07/21
18:20
07/21/17
18:20
Periodicals
U.S. regulators to go over MetLife suit at July 28 meeting, Reuters says »

Leaders at the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 14

    Aug

  • 15

    Aug

OTEX

OpenText

$33.06

-0.02 (-0.06%)

, COVS

Covisint

18:11
07/21/17
07/21
18:11
07/21/17
18:11
Hot Stocks
OpenText says Covisint proposal shows 'compelling' overall value »

OpenText (OTEX) announced…

OTEX

OpenText

$33.06

-0.02 (-0.06%)

COVS

Covisint

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

TOSBF

Toshiba, also use TOSYY

$2.47

0.1002 (4.23%)

, TOSYY

Toshiba, also use TOSBF

$14.90

0.8 (5.67%)

17:39
07/21/17
07/21
17:39
07/21/17
17:39
Periodicals
Toshiba sees bringing in about $360 in profit from Landis+Gyr IPO, Nikkei says »

Toshiba sees reaping…

TOSBF

Toshiba, also use TOSYY

$2.47

0.1002 (4.23%)

TOSYY

Toshiba, also use TOSBF

$14.90

0.8 (5.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$117.38

0.37 (0.32%)

17:38
07/21/17
07/21
17:38
07/21/17
17:38
Periodicals
Breaking Periodicals news story on Monsanto »

Monsanto says some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSFG

First Savings Financial Group

$53.02

0.095 (0.18%)

17:34
07/21/17
07/21
17:34
07/21/17
17:34
Hot Stocks
First Savings Financial Group , First National Bank of Odon to merge »

First Savings Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAUH

National American University

$2.36

-0.0236 (-0.99%)

17:26
07/21/17
07/21
17:26
07/21/17
17:26
Hot Stocks
National American University to acquire H-PU, terms not disclosed »

National American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

QEP

QEP Resources

$9.22

-0.27 (-2.85%)

17:25
07/21/17
07/21
17:25
07/21/17
17:25
Hot Stocks
QEP Resources names Mary Shafer-Malicki to board of directors »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CLSN

Celsion

$1.85

-0.07 (-3.65%)

17:18
07/21/17
07/21
17:18
07/21/17
17:18
Syndicate
Celsion files to sell 4.87M shares of common stock for holders »

Issuable upon exercise of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REED

Reed's

16:54
07/21/17
07/21
16:54
07/21/17
16:54
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Raptor/Harbor Reeds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBA

Urstadt Biddle

$20.86

0.28 (1.36%)

, UBP

Urstadt Biddle Properties Inc.

$18.50

0.721 (4.06%)

16:53
07/21/17
07/21
16:53
07/21/17
16:53
Hot Stocks
Urstadt Biddle Properties acquires Waldwick Plaza in Waldwick, NJ »

Urstadt Biddle Properties…

UBA

Urstadt Biddle

$20.86

0.28 (1.36%)

UBP

Urstadt Biddle Properties Inc.

$18.50

0.721 (4.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$76.21

0.7 (0.93%)

16:51
07/21/17
07/21
16:51
07/21/17
16:51
Hot Stocks
Perrigo board suspends CFO search during CEO search »

The company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$19.38

0.07 (0.36%)

, ENTL

Entellus Medical

$17.03

-0.71 (-4.00%)

16:47
07/21/17
07/21
16:47
07/21/17
16:47
Hot Stocks
Breaking Hot Stocks news story on KKR, Entellus Medical »

KKR Fund Holdings reports…

KKR

KKR

$19.38

0.07 (0.36%)

ENTL

Entellus Medical

$17.03

-0.71 (-4.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CAG

Conagra Brands

$33.88

0.13 (0.39%)

16:43
07/21/17
07/21
16:43
07/21/17
16:43
Syndicate
Breaking Syndicate news story on Conagra Brands »

Conagra Brands files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.20

-0.26 (-4.02%)

16:32
07/21/17
07/21
16:32
07/21/17
16:32
Hot Stocks
AK Steel to increase prices for carbon flat-rolled steel products »

AK Steel said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

16:30
07/21/17
07/21
16:30
07/21/17
16:30
Options
Preliminary option volume of 19.1M today »

Preliminary option volume…

GE

General Electric

$25.91

-0.78 (-2.92%)

, MSFT

Microsoft

$73.79

-0.43 (-0.58%)

16:27
07/21/17
07/21
16:27
07/21/17
16:27
General news
On The Fly: Top stock stories for Friday »

Stocks opened in negative…

GE

General Electric

$25.91

-0.78 (-2.92%)

MSFT

Microsoft

$73.79

-0.43 (-0.58%)

V

Visa

$99.60

1.49 (1.52%)

MNT

Mentor

AMPH

Amphastar

$18.45

0.53 (2.96%)

COF

Capital One

$87.94

6.93 (8.55%)

ATHN

athenahealth

$155.93

12.13 (8.44%)

SYF

Synchrony

$30.87

1.34 (4.54%)

PLUG

Plug Power

$2.44

0.32 (15.09%)

WMT

Wal-Mart

$76.15

0.13 (0.17%)

EBAY

eBay

$36.61

-0.57 (-1.53%)

NCR

NCR Corp.

$39.43

-3.55 (-8.26%)

MANH

Manhattan Associates

$43.15

-4.28 (-9.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 08

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 18

    Aug

  • 05

    Sep

  • 02

    Oct

  • 16

    Nov

  • 20

    Feb

TERP

TerraForm Power

16:26
07/21/17
07/21
16:26
07/21/17
16:26
Earnings
TerraForm Power reports Q4 net income loss $135M vs loss of $156M in Q415 »

Reports Q4 revenue $135M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

16:22
07/21/17
07/21
16:22
07/21/17
16:22
Periodicals
U.S. drops charges against ex-JPMorgan traders in 'London Whale' case, CNBC says »

The U.S. has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CMG

Chipotle

$345.34

-10.71 (-3.01%)

16:20
07/21/17
07/21
16:20
07/21/17
16:20
Periodicals
Chipotle holder sues company after latest food scare, Bloomberg says »

A shareholder of Chipotle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

RPRX

Repros Therapeutics

$0.37

-0.0249 (-6.30%)

16:18
07/21/17
07/21
16:18
07/21/17
16:18
Syndicate
Breaking Syndicate news story on Repros Therapeutics »

Repros Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CARV

Carver Bancorp

$3.30

0.23 (7.49%)

16:17
07/21/17
07/21
16:17
07/21/17
16:17
Hot Stocks
Carver Bancorp receives Nasdaq letter of noncompliance »

Carver Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
07/21/17
07/21
16:17
07/21/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYH

Community Health

$9.27

0.01 (0.11%)

, HCA

HCA Holdings

$85.72

-0.04 (-0.05%)

16:16
07/21/17
07/21
16:16
07/21/17
16:16
Hot Stocks
Community Health to sell Sebring, Florida hospital to HCA Holdings »

Community Health Systems…

CYH

Community Health

$9.27

0.01 (0.11%)

HCA

HCA Holdings

$85.72

-0.04 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 02

    Aug

  • 23

    Aug

$NYE

NYSE Market Internals

16:16
07/21/17
07/21
16:16
07/21/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

16:14
07/21/17
07/21
16:14
07/21/17
16:14
Hot Stocks
Morgan Stanley CFO Pruzan sells 25.8K shares »

Jonathan Pruzan, CFO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.